| . | Overall population (N = 340) . | MR non-improvers (N = 140) . | MR improvers (N = 200) . | P- value . |
|---|---|---|---|---|
| LV EDV, % | −10 ± 19 | −2 ± 18 | −16 ± 18 | <0.001 |
| LV ESV, % | −17 ± 23 | −7 ± 22 | −24 ± 20 | <0.001 |
| LVEF, % | 31 ± 43 | 21 ± 40 | 37 ± 43 | 0.001 |
| LV GLS, % | 35 ± 7 | 24 ± 8 | 43 ± 10 | 0.178 |
| LAVi, % | −3 ± 34 | 3.5 ± 37 | −7 ± 30 | 0.004 |
| LARS, % | 31 ± 5 | 10 ± 5 | 46 ± 8 | <0.001 |
| TAPSE, % | 9 ± 36 | 11 ± 35 | 7 ± 37 | 0.475 |
| TR max velocity, % | 6 ± 59 | 1.4 ± 19 | 8.9 ± 78 | 0.337 |
| . | Overall population (N = 340) . | MR non-improvers (N = 140) . | MR improvers (N = 200) . | P- value . |
|---|---|---|---|---|
| LV EDV, % | −10 ± 19 | −2 ± 18 | −16 ± 18 | <0.001 |
| LV ESV, % | −17 ± 23 | −7 ± 22 | −24 ± 20 | <0.001 |
| LVEF, % | 31 ± 43 | 21 ± 40 | 37 ± 43 | 0.001 |
| LV GLS, % | 35 ± 7 | 24 ± 8 | 43 ± 10 | 0.178 |
| LAVi, % | −3 ± 34 | 3.5 ± 37 | −7 ± 30 | 0.004 |
| LARS, % | 31 ± 5 | 10 ± 5 | 46 ± 8 | <0.001 |
| TAPSE, % | 9 ± 36 | 11 ± 35 | 7 ± 37 | 0.475 |
| TR max velocity, % | 6 ± 59 | 1.4 ± 19 | 8.9 ± 78 | 0.337 |
Values are presented as mean ± SD. Values in bold have a P-value < 0.05.
EDV, end-diastolic volume; ESV, end-systolic volume; LAVi, left atrial volume index; TR, tricuspid regurgitation.
| . | Overall population (N = 340) . | MR non-improvers (N = 140) . | MR improvers (N = 200) . | P- value . |
|---|---|---|---|---|
| LV EDV, % | −10 ± 19 | −2 ± 18 | −16 ± 18 | <0.001 |
| LV ESV, % | −17 ± 23 | −7 ± 22 | −24 ± 20 | <0.001 |
| LVEF, % | 31 ± 43 | 21 ± 40 | 37 ± 43 | 0.001 |
| LV GLS, % | 35 ± 7 | 24 ± 8 | 43 ± 10 | 0.178 |
| LAVi, % | −3 ± 34 | 3.5 ± 37 | −7 ± 30 | 0.004 |
| LARS, % | 31 ± 5 | 10 ± 5 | 46 ± 8 | <0.001 |
| TAPSE, % | 9 ± 36 | 11 ± 35 | 7 ± 37 | 0.475 |
| TR max velocity, % | 6 ± 59 | 1.4 ± 19 | 8.9 ± 78 | 0.337 |
| . | Overall population (N = 340) . | MR non-improvers (N = 140) . | MR improvers (N = 200) . | P- value . |
|---|---|---|---|---|
| LV EDV, % | −10 ± 19 | −2 ± 18 | −16 ± 18 | <0.001 |
| LV ESV, % | −17 ± 23 | −7 ± 22 | −24 ± 20 | <0.001 |
| LVEF, % | 31 ± 43 | 21 ± 40 | 37 ± 43 | 0.001 |
| LV GLS, % | 35 ± 7 | 24 ± 8 | 43 ± 10 | 0.178 |
| LAVi, % | −3 ± 34 | 3.5 ± 37 | −7 ± 30 | 0.004 |
| LARS, % | 31 ± 5 | 10 ± 5 | 46 ± 8 | <0.001 |
| TAPSE, % | 9 ± 36 | 11 ± 35 | 7 ± 37 | 0.475 |
| TR max velocity, % | 6 ± 59 | 1.4 ± 19 | 8.9 ± 78 | 0.337 |
Values are presented as mean ± SD. Values in bold have a P-value < 0.05.
EDV, end-diastolic volume; ESV, end-systolic volume; LAVi, left atrial volume index; TR, tricuspid regurgitation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
